The reason semaglutide (Ozempic) became the most consequential metabolic research compound of the past decade is not its clinical name recognition — it is the depth of the mechanistic story behind it: a precisely engineered analogue of a short-lived endogenous hormone, redesigned at the molecular level to activate the same receptor for seven days instead of two minutes. Understanding how semaglutide works at the receptor level, how the SUSTAIN trial programme characterised its metabolic profile, and how it sits within the broader GLP-1 research landscape is essential context for anyone studying incretin pharmacology, metabolic signalling, or the biology of receptor agonist engineering.
This article covers the molecular biology of glucagon-like peptide-1 (GLP-1), the structural engineering of semaglutide as a long-acting analogue, the GLP-1 receptor signalling cascade, the SUSTAIN trial programme, and the tissue distribution of GLP-1 receptor expression that explains the breadth of metabolic effects characterised in published research. Related compounds including tirzepatide and retatrutide are discussed in the context of expanding incretin receptor research.
Compliance notice: Semaglutide is a prescription-only medication (POM) in the United Kingdom and many other jurisdictions. Pure Grade Labs supplies semaglutide strictly as a research chemical for in vitro and preclinical laboratory use. This article discusses published clinical trial parameters and molecular pharmacology research only. It does not constitute medical advice, prescriptive guidance, or treatment recommendations. Not for human consumption.
Key Takeaways
- Semaglutide is a 94% homologous analogue of human GLP-1, engineered with two amino acid substitutions and a C18 fatty acid chain to extend plasma half-life from ~2 minutes to approximately 7 days.
- The GLP-1 receptor is a Gs-coupled GPCR — activation triggers adenylyl cyclase → cAMP elevation → PKA/EPAC activation → glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and hypothalamic satiety signalling.
- SUSTAIN-6 enrolled 3,297 participants over 2 years and demonstrated cardiovascular outcome effects of semaglutide in a high cardiovascular risk population — a finding that expanded the research scope beyond glycaemic endpoints.
- GLP-1 receptors are expressed in pancreatic beta cells, hypothalamic nuclei, gastric tissue, cardiovascular tissue, and the kidney — explaining why semaglutide research spans glycaemic, cardiometabolic, and appetite-related endpoints simultaneously.
- Semaglutide is a prescription-only medication. Pure Grade Labs supplies it as a research chemical for laboratory use only. Not for human consumption.
Research-Grade Semaglutide
HPLC-verified purity. Batch-specific COA. Prescription-only medication — supplied strictly as a research chemical for laboratory use. Not for human consumption.
Browse Research Catalogue →What Is GLP-1? The Incretin Hormone Behind Semaglutide
Glucagon-like peptide-1 (GLP-1) is an endogenous incretin hormone — a peptide secreted from the gastrointestinal tract in response to nutrient ingestion that potentiates glucose-stimulated insulin secretion from the pancreas. It is produced primarily by intestinal L-cells located in the distal small intestine and colon, where it is cleaved from proglucagon via post-translational processing by prohormone convertase 1/3 (PC1/3). The active forms of GLP-1 — GLP-1(7-36)-amide and GLP-1(7-37) — are released into the portal circulation following carbohydrate and fat intake.
The defining pharmacological characteristic of endogenous GLP-1 is its extremely short plasma half-life of approximately 1-2 minutes. This rapid degradation is mediated primarily by dipeptidyl peptidase-4 (DPP-4), a serine protease that cleaves the N-terminal His-Ala dipeptide from GLP-1's sequence, rendering the molecule biologically inactive. DPP-4 is abundantly expressed on endothelial cells throughout the circulation, meaning that a substantial fraction of secreted GLP-1 is inactivated before it even reaches the systemic circulation from the portal system. A secondary clearance mechanism — renal filtration — further limits the duration of GLP-1 action.
This pharmacokinetic limitation of native GLP-1 — powerful pharmacodynamic effects but an extremely short window of action — was the central design problem that drove the development of GLP-1 receptor agonist analogues. The goal was to engineer compounds that activated the GLP-1 receptor with equivalent or greater potency while resisting DPP-4 degradation and extending plasma half-life to a therapeutically and experimentally useful duration. Semaglutide represents the most refined solution to this engineering challenge yet developed for selective GLP-1 receptor agonism.
Semaglutide: Molecular Engineering for Half-Life Extension
Semaglutide is a 31-amino acid peptide developed by Novo Nordisk that shares 94% sequence homology with human GLP-1. This high homology preserves the receptor binding geometry required for full GLP-1 receptor agonism while two targeted modifications address the half-life limitation.
Modification 1: DPP-4 Resistance
The first modification is the substitution of alanine at position 8 of the native GLP-1 sequence with the non-natural amino acid alpha-aminoisobutyric acid (Aib). DPP-4 cleaves the His-Ala dipeptide at positions 7-8 — by replacing Ala at position 8 with Aib, semaglutide becomes sterically resistant to DPP-4 cleavage. This single substitution eliminates the primary enzymatic degradation pathway without materially altering GLP-1 receptor binding affinity.
Modification 2: Albumin Binding via Fatty Acid Chain
The second — and more pharmacokinetically significant — modification is the attachment of a C18 fatty diacid chain to lysine at position 26 via a bifunctional hydrophilic linker. This fatty acid modification enables reversible non-covalent binding to human serum albumin in the circulation. Since albumin has a plasma half-life of approximately 19 days and is not filtered by the kidneys, molecules bound to albumin are protected from renal clearance. The binding is reversible — semaglutide cycles between albumin-bound (inactive reservoir) and free (active) states, creating an equilibrium that sustains plasma concentrations over approximately 7 days.
A second amino acid substitution at position 34 (arginine replacing lysine) prevents the fatty acid from mistakenly attaching to this position during synthesis, ensuring site-specific modification at position 26. The result is a precisely engineered molecule: 94% identical to native GLP-1 in sequence, fully resistant to DPP-4 degradation at position 8, and sustained in the circulation for approximately 7 days through albumin binding at position 26.
A research pharmacologist describing the half-life engineering of semaglutide to a postgraduate student framed it this way: "Native GLP-1 is a sprint — it fires in two minutes and it's gone. The problem is that the receptor does extraordinary things when it's activated, but you can't study those effects with a compound that's degraded before it reaches peripheral tissue. What Novo Nordisk built with semaglutide is essentially a controlled-release mechanism encoded into the molecule itself — the albumin binding is the slow-release matrix. Every time the molecule dissociates from albumin, it can bind receptors; every time it re-associates, it's protected again. The result is a seven-day window to study what sustained GLP-1 receptor activation actually does in complex biological systems."
Illustrative research context — based on published mechanistic literature on GLP-1 analogue design.
The GLP-1 Receptor Signalling Cascade
The GLP-1 receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) — a subfamily of GPCRs defined by a large extracellular N-terminal domain that forms part of the ligand binding interface. Unlike class A GPCRs (which include the beta-adrenergic receptor and many drug targets), class B GPCRs use a two-domain binding mechanism: the C-terminal portion of the GLP-1 ligand binds the extracellular domain, while the N-terminal portion engages the transmembrane bundle to activate the receptor. This binding geometry has important implications for agonist design and is why even small sequence changes can substantially alter receptor binding affinity.
Gs Coupling and cAMP Elevation
The GLP-1 receptor is primarily coupled to the Gs protein (stimulatory G protein). When semaglutide binds and activates the GLP-1R, the receptor undergoes a conformational change that catalyses GDP-to-GTP exchange on the Gs alpha subunit. The activated Gs alpha-GTP dissociates and stimulates adenylyl cyclase, the enzyme that converts ATP to cyclic adenosine monophosphate (cAMP). The resulting elevation of intracellular cAMP is the primary second messenger of GLP-1R activation and is responsible for the downstream functional responses.
PKA and EPAC: Two cAMP Effector Pathways
Elevated cAMP activates two principal effector proteins in pancreatic beta cells: protein kinase A (PKA) and the exchange protein directly activated by cAMP (EPAC, specifically EPAC2 in beta cells). PKA phosphorylates multiple substrates involved in the exocytotic machinery for insulin granule release — including L-type voltage-dependent calcium channels (increasing Ca2+ influx), KATP channel subunits (contributing to membrane depolarisation), and synaptotagmin-like proteins involved in granule docking and fusion. EPAC2 (also known as Rap guanine nucleotide exchange factor 4) activates Rap1, which further amplifies exocytosis through distinct cytoskeletal and vesicular trafficking mechanisms. The two pathways work in parallel and synergistically — PKA primarily amplifies the triggering pathway, while EPAC2 amplifies the amplifying pathway of insulin secretion.
Critically, both pathways are glucose-dependent: insulin secretion potentiation by GLP-1R activation requires concurrent glucose stimulation to produce membrane depolarisation via KATP channel closure. In the absence of sufficient glucose, GLP-1R agonism does not drive insulin secretion — a mechanistic safeguard that distinguishes this class of compounds from sulfonylureas, which close KATP channels independently of glucose.
Glucagon Suppression and Gastric Emptying
GLP-1 receptors are also expressed in pancreatic alpha cells, where activation suppresses glucagon secretion — reducing hepatic glucose output and contributing to postprandial glucose regulation. The mechanism of GLP-1R-mediated glucagon suppression in alpha cells is complex and may involve both direct receptor activation on alpha cells and paracrine signalling from adjacent beta cells via somatostatin or insulin itself. In gastric smooth muscle and enteric nerves, GLP-1R activation slows gastric emptying by reducing the rate of gastric antral contractions, attenuating the rate of nutrient delivery to the small intestine and blunting postprandial glucose excursions.
Central GLP-1 Receptor Effects: Hypothalamus and Brain
One of the most pharmacologically significant features of semaglutide research is the evidence for central nervous system GLP-1 receptor activation as a contributor to metabolic effects. GLP-1 receptors are expressed in multiple hypothalamic nuclei — including the arcuate nucleus (ARC), the paraventricular nucleus (PVN), and the nucleus tractus solitarius (NTS) in the brainstem — where they modulate appetite-regulating neuropeptide circuits.
In the arcuate nucleus, GLP-1R activation stimulates pro-opiomelanocortin (POMC) neurons — a major anorexigenic pathway — while inhibiting neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons, which are orexigenic. This central appetite circuit modulation contributes to reduced caloric intake in research models and is distinct from the peripheral gastric emptying effect — both mechanisms can operate simultaneously and additively.
Whether peripherally administered semaglutide crosses the blood-brain barrier or acts via circumventricular organs (areas lacking a tight blood-brain barrier, such as the area postrema and median eminence) to access hypothalamic GLP-1R populations remains an active area of research. Experimental evidence in rodent models suggests both direct CNS penetration and peripheral-to-central signalling via vagal afferents contribute to the central appetite effects.
The SUSTAIN Trial Programme: Clinical Characterisation of Semaglutide
Semaglutide's clinical profile was characterised across the SUSTAIN programme — a series of randomised controlled trials evaluating subcutaneous once-weekly semaglutide in participants with type 2 diabetes across different comparators, populations, and endpoints. The PIONEER programme subsequently evaluated an oral semaglutide formulation.
SUSTAIN-1 (2016): Placebo-Controlled Efficacy
SUSTAIN-1 (Sorli et al., Lancet Diabetes Endocrinol 2017) enrolled 388 participants with type 2 diabetes on diet and exercise management, randomising them to semaglutide 0.5mg, semaglutide 1mg, or placebo over 30 weeks. The trial established the baseline efficacy profile of semaglutide: HbA1c reductions of −1.45% (0.5mg) and −1.55% (1mg) vs +0.02% for placebo, alongside statistically significant body weight reductions.
SUSTAIN-6 (2016): Cardiovascular Outcomes
SUSTAIN-6 (Marso et al., NEJM 2016) is the landmark trial in the semaglutide evidence base. It enrolled 3,297 participants with type 2 diabetes and high cardiovascular risk — defined as established cardiovascular disease, chronic kidney disease, or multiple risk factors — in a 2-year double-blind trial comparing semaglutide (0.5mg and 1mg) vs placebo. The primary endpoint was first occurrence of a major adverse cardiovascular event (MACE) — defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.
Published results showed a 26% relative risk reduction in the primary MACE endpoint in the semaglutide arm vs placebo — a statistically significant finding that converted the non-inferiority trial design into a superiority outcome. This established semaglutide as a GLP-1 compound with documented cardiovascular outcome effects, and drove substantial subsequent research interest in the cardiovascular mechanisms of GLP-1 receptor activation.
SUSTAIN-7 (2018): Head-to-Head vs Dulaglutide
SUSTAIN-7 (Pratley et al., Lancet Diabetes Endocrinol 2018) provided a direct head-to-head comparison between semaglutide 0.5mg and 1mg vs dulaglutide 0.75mg and 1.5mg in 1,201 participants with type 2 diabetes over 40 weeks. Semaglutide achieved statistically superior HbA1c reductions compared to both doses of dulaglutide and produced significantly greater body weight reductions. This trial positioned semaglutide as the highest-efficacy GLP-1 mono-agonist available at that time and established the class benchmark against which subsequent compounds — including tirzepatide — would be compared.
PIONEER Programme: Oral Semaglutide
The PIONEER programme evaluated an oral formulation of semaglutide (Rybelsus) — a significant pharmacological achievement, as peptides are typically degraded in the gastrointestinal tract before absorption. Oral semaglutide is co-formulated with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that facilitates gastric absorption by transiently and locally increasing gastric mucosa permeability and protecting semaglutide from proteolysis in the stomach. PIONEER-6 demonstrated cardiovascular safety of the oral formulation in a non-inferiority trial, extending the cardiovascular evidence base.
At a metabolic research symposium, a presenter describing the SUSTAIN-6 results made a point that crystallised the broader significance of the finding: the trial had been designed as a safety study — the regulatory bar was simply to show that semaglutide didn't increase cardiovascular risk. When the data came back showing a 26% reduction in MACE, it reframed the entire research agenda. It wasn't just a diabetes compound anymore. The cardiovascular endpoint data opened entirely new research questions about the mechanisms linking GLP-1 receptor activation to cardiovascular tissue biology — endothelial function, cardiac remodelling, inflammatory pathways, plaque stability. The molecule had revealed a pharmacological surface area far broader than its initial research framing.
Illustrative research context — based on published SUSTAIN-6 findings and subsequent mechanistic commentary.
Research the Full GLP-1 Landscape
Semaglutide, tirzepatide, retatrutide — HPLC-verified, batch-specific COA, research-grade supply. Prescription-only medications supplied as research chemicals only.
View Research Catalogue →GLP-1 Receptor Expression in Cardiovascular and Peripheral Tissue
The breadth of metabolic endpoints characterised in semaglutide research reflects the wide tissue distribution of GLP-1 receptor expression. Beyond the pancreas and hypothalamus, GLP-1R is expressed in several additional tissue types that explain the observed cardiovascular and metabolic effects.
Cardiovascular Tissue
GLP-1 receptors are expressed in cardiomyocytes, vascular endothelial cells, smooth muscle cells, and immune cells associated with atherosclerotic plaque. Experimental data from rodent models and human in vitro studies has suggested that GLP-1R activation in cardiovascular tissue may influence: cardiac contractility and output, endothelial nitric oxide synthase (eNOS) activity and endothelial function, vascular smooth muscle relaxation, endothelial cell inflammatory signalling (including ICAM-1 and NF-κB pathways), and macrophage foam cell formation in atherosclerotic lesion models. These mechanisms are candidates for explaining the SUSTAIN-6 cardiovascular outcome data, though the relative contribution of direct cardiac/vascular GLP-1R effects vs metabolic risk factor improvements (HbA1c, body weight, blood pressure) remains an active area of investigation.
Kidney
GLP-1 receptors are expressed in the kidney — specifically in glomerular endothelial cells, podocytes, and the proximal tubule. Research models have suggested GLP-1R activation may reduce glomerular hyperfiltration, decrease tubular sodium reabsorption (contributing to natriuresis), and modulate inflammatory pathways in renal tissue. These mechanisms provide a potential pharmacological basis for the kidney outcome data reported in semaglutide trials and are an expanding area of GLP-1 receptor research.
SUSTAIN Trial Programme: Key Data Points
| Trial | Year | N | Duration | Primary Focus | Key Finding |
|---|---|---|---|---|---|
| SUSTAIN-1 | 2017 | 388 | 30 weeks | vs Placebo (monotherapy) | HbA1c −1.45% / −1.55% vs +0.02% |
| SUSTAIN-6 | 2016 | 3,297 | 2 years | Cardiovascular outcomes (MACE) | 26% MACE reduction vs placebo |
| SUSTAIN-7 | 2018 | 1,201 | 40 weeks | vs Dulaglutide (head-to-head) | Superior HbA1c and weight vs both dulaglutide doses |
| PIONEER-6 | 2019 | 3,183 | 15.9 months | CV safety of oral semaglutide | Non-inferiority demonstrated; 21% MACE reduction trend |
Semaglutide in the Context of Expanding Incretin Research
Semaglutide's clinical trial programme established the performance ceiling for selective GLP-1 mono-agonism — and provided the benchmark against which dual and triple incretin receptor agonists have since been measured. Tirzepatide (Mounjaro), by adding GIP receptor agonism to GLP-1R activation, demonstrated in SURPASS-2 (2021) that the semaglutide benchmark could be surpassed through dual receptor engagement — producing superior HbA1c and weight outcomes across all tested doses in a direct head-to-head RCT.
Retatrutide extends this further by adding glucagon receptor agonism to the GIP/GLP-1 dual agonism of tirzepatide — creating a triple incretin agonist. Phase 2 data published in NEJM (2023) reported body weight reductions of up to 24.2% over 48 weeks. The progression from semaglutide through tirzepatide to retatrutide represents a natural experiment in receptor pharmacology: holding constant the GLP-1R component while systematically adding receptor targets, and measuring the incremental metabolic effects at each step.
For researchers studying incretin receptor biology, this pharmacological hierarchy offers a powerful research framework — with semaglutide as the selective GLP-1R reference compound, tirzepatide as the GIP/GLP-1 dual control, and retatrutide as the triple agonist at the frontier. All three are available from Pure Grade Labs as HPLC-verified research chemicals.
Frequently Asked Questions
What is the mechanism of action of semaglutide?
Semaglutide is a GLP-1 receptor agonist. It binds the GLP-1 receptor — a class B Gs-coupled GPCR — and activates adenylyl cyclase, elevating intracellular cAMP. This triggers PKA and EPAC2 activation in pancreatic beta cells, potentiating glucose-dependent insulin secretion. Simultaneously, glucagon secretion from alpha cells is suppressed, gastric emptying is slowed, and hypothalamic appetite circuits are modulated through GLP-1R activation in the arcuate nucleus and nucleus tractus solitarius.
Why does semaglutide have a 7-day half-life when native GLP-1 only lasts 2 minutes?
Native GLP-1 is rapidly degraded by DPP-4 enzyme, which cleaves the N-terminal His-Ala dipeptide. Semaglutide incorporates two modifications: replacement of alanine at position 8 with Aib (conferring DPP-4 resistance) and attachment of a C18 fatty acid chain via linker at lysine-26 (enabling albumin binding). Albumin binding protects semaglutide from renal clearance and creates a circulating reservoir that sustains plasma concentrations over approximately 7 days.
What did SUSTAIN-6 find?
SUSTAIN-6 (Marso et al., NEJM 2016) was a 2-year, placebo-controlled cardiovascular outcomes trial enrolling 3,297 participants with type 2 diabetes and high cardiovascular risk. It demonstrated a statistically significant 26% relative risk reduction in the primary MACE endpoint (CV death, non-fatal MI, non-fatal stroke) in the semaglutide group vs placebo — an unexpected superiority finding in a non-inferiority trial that established semaglutide as a compound with documented cardiovascular effects beyond glycaemic mechanisms.
Is semaglutide legal to buy in the UK?
Semaglutide is a prescription-only medication (POM) in the UK under the Human Medicines Regulations 2012. As a licensed medicine (Ozempic, Wegovy), it requires a valid prescription from a registered prescriber. Pure Grade Labs supplies semaglutide exclusively as a research chemical for laboratory research purposes — a distinct regulatory classification. Not for human consumption.
How does GLP-1 receptor activation affect the brain?
GLP-1 receptors are expressed in hypothalamic nuclei including the arcuate nucleus and paraventricular nucleus, as well as the nucleus tractus solitarius in the brainstem. Activation stimulates anorexigenic POMC neurons and inhibits orexigenic NPY/AgRP neurons in the arcuate nucleus, contributing to reduced appetite signalling. Research has investigated both direct CNS penetration of semaglutide and peripheral-to-central signalling via circumventricular organs and vagal afferents as mechanisms for these central effects.
How does semaglutide compare to tirzepatide?
Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. In the SURPASS-2 head-to-head RCT (2021), tirzepatide at all three tested doses demonstrated statistically superior HbA1c and body weight outcomes vs semaglutide 1mg. The superior effect sizes of tirzepatide are attributed to the additional GIP receptor activation component, which engages distinct downstream signalling pathways — particularly in adipose tissue where GIP receptor density is substantially higher than GLP-1 receptor density.
Research-Grade Supply for Serious Research
Semaglutide, tirzepatide, and retatrutide — HPLC-verified, batch-specific COA, QR-authenticated. Prescription-only medications supplied as research chemicals. Not for human consumption.
Browse Full Catalogue →Summary
Semaglutide's significance in metabolic research derives from a precise confluence of molecular engineering and pharmacological breadth. At the structural level, two amino acid modifications and a fatty acid chain transform a 2-minute endogenous incretin fragment into a 7-day receptor agonist — opening a research window that the native hormone simply cannot provide. At the receptor level, GLP-1R activation drives a cAMP → PKA/EPAC cascade with effects in pancreatic beta and alpha cells, gastric tissue, hypothalamic nuclei, cardiovascular tissue, and the kidney — explaining why the SUSTAIN programme found metabolic effects spanning glycaemic, cardiovascular, and weight endpoints simultaneously.
SUSTAIN-6's cardiovascular outcome findings in 3,297 participants over 2 years, and SUSTAIN-7's head-to-head superiority vs dulaglutide, established semaglutide as the reference compound for GLP-1 mono-agonism — a benchmark subsequently exceeded by dual agonist tirzepatide and triple agonist retatrutide. For researchers studying this pharmacological hierarchy, all three compounds are available from Pure Grade Labs as HPLC-verified research chemicals with batch-specific COA documentation. Semaglutide is a prescription-only medication — supplied strictly as a research chemical for laboratory use only. Not for human consumption.
References
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844. PMID: 27633186
- Pratley RE, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286. PMID: 29397366
- Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260. PMID: 28110911
- Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841–851. PMID: 31185157
- Nauck MA, Quast DR. Cardiovascular Safety and Benefits of Semaglutide in Patients with Type 2 Diabetes. Cardiology. 2021;146(4):508–524. PMID: 33906191
- Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165. PMID: 16517403
- Lau J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370–7380. PMID: 26308095
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–1439. PMID: 17928588
Disclaimer: This article is for informational and research purposes only. Semaglutide is a prescription-only medication in many jurisdictions including the United Kingdom. Pure Grade Labs supplies semaglutide strictly as a research chemical for laboratory use — not as a licensed medicine and not for human consumption. This content does not constitute medical advice, prescriptive guidance, or treatment recommendations of any kind. Researchers should consult the primary literature and applicable regulatory frameworks before working with this compound. For research purposes only. Not for human consumption.